Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Alectinib in RET-rearranged NSCLC or RET-mutated Thyroid Cancer
NCT03131206Phase 2Terminated
- Sponsor
- Dana-Farber Cancer Institute
- Start
- Jun 2017
- Primary completion
- Nov 2018
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 2 trial of alectinib in non-small cell lung cancer (NSCLC), thyroid cancer, sponsored by Dana-Farber Cancer Institute. Started Jun 2017; status: terminated.
02
Drugs
alectinib
03
Conditions
non-small cell lung cancer (NSCLC)thyroid cancer
Beyond the preview
Go deeper on NCT03131206.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03131206.